Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
1. 系统已在2025-09-10 11:47:03对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接: 需要2025年的这篇文献的补充资料，谢谢！
其他信息:
需要2025年的这篇文献的补充资料，谢谢！
AJ Sanyal, PN Newsome, I Kliers…
… England Journal of …, 2025
Mass Medical Soc
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, is a candidate for the treatment of metabolic dysfunction–associated steatohepatitis (MASH). Methods In this ongoing phase 3, multicenter, randomized, double-blind, placebo-controlled trial, we assigned 1197 patients with biopsy-defined MASH and fibrosis stage 2 or 3 in a 2: 1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo for 240 weeks. The results of a planned interim analysis conducted at week 72 involving the first 800 …
